[Parsalmide, a new synthetic substance, in inflammatory and arthrosic arthropathies. Double-blind controlled clinical trial].
The double-blind, between-patient experimental technique was employed to investigate the anti-inflammatory, antalgic and myorelaxant activity of a new synthetic compound, parsalmide. 30 patients suffering from arthrosic and inflammatory arthropathies in various sites and in newly acute phase, were treated with the substance which was assigned at random to 2 experimental groups; phenylbutazone was adopted for comparison purposes. Both substances under study proved to have good anti-inflammatory and antalgic action, although in the case of certain parameters, parsalmide was definitely superior to the control drug. The antalgic and myorelaxant activities of parsalmide were statistically superior to those of phenylbutazone. Tolerance was "very good" in 93% of cases treated with parsalmide "very good" or "good" in 86.6% of the cases treated with phenylbutazone.
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D001549:Benzamides / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007592:Joint Diseases / Q000188:drug therapy*; D008297:Male; D010653:Phenylbutazone / Q000627:therapeutic use
D000894:Anti-Inflammatory Agents, Non-Steroidal; D001549:Benzamides; D010653:Phenylbutazone
Parsalmide, nuova sostanza di sintesi nelle artropatie artrosiche e infiammatorie. Sperimentazione clinica controllata in "double-blind"